As the various new BPH therapies try and mark out their role in the management of the condition, this is an interesting and useful addition to the literature. Patients were clinically screened for an obstructive median lobe on cystoscopy, which traditionally may have precluded them from UroLift®. Of 71 screened, 45 were included. Baseline criteria were the same as those for the LIFT study (age>50, IPSS>13, Qmax<12ml/s and 30-80cc prostate volume). A consistent improvement in International Prostate Symptom Score (IPSS) score (13.5 points) was demonstrated at 1, 3, 6 and 12 months. This was comparable with those in the original LIFT study with only lateral lobe enlargement. The authors have described their technique for deploying implants to treat the median lobe that involves pulling the intravesical portion into the prostatic fossa and pinned to one side.